GLP-1 RAs tied to greater risk of diabetic retinopathy progression than SGLT-2is: study
The association was driven by the increased risk of tractional retinal detachment, researchers say.
In patients with diabetes and established diabetic retinopathy, treatment with GLP-1 receptor agonists is associated with increased risks of diabetic retinopathy progression compared with SGLT-2 inhibitors, according to a study in Diabetes, Obesity and Metabolism.
Researchers in Taiwan examined the effects of GLP-1 receptor agonists (GLP-1 RAs) and SGLT-2 inhibitors (SGLT-2is) on the development or progression of diabetic retinopathy.
